Hello and welcome back to Equity Tech Tech Runches Venture Capital, focused

podcast where we unpack the numbers behind the headlines.

This, of course, is our Wednesday episode,

where we niche down to a single topic,

and today we are looking at something that is both fun, interesting and you may have some personal experience in, namely,

Psychodelics. Now don't raise your hand if you've done Psychodelics, Natasha or Danny, but I'm glad you're here with me to talk about this.

It's a fascinating topic, you know, I feel like drugs only come up with our friends,

because we've never done drugs.

But Danny, this was a core part of your thesis for 2020 and I'm curious why you thought

psychedelics were going to be hot this year and are we leaving up to that hype?

Well obviously mental health has been you know hugely on people'sars. I mean ironically even prior to the

pandemic. I think when you look at the scale the mental health challenges in

countries like the United States in Europe across Asia, traditional medication is

just not proven effective, whether that's antidepressants, talk therapy,

other types of therapy or counseling. There's been a huge, huge wave of wellness startups,

calm and head space, that are trying to solve something very foundational, and yet none of it seems to be working.

You know, and people aren't any happier today than they were two decades ago.

And so when you're looking at the frontiers of science, of innovation, and asking, what's going to change that pattern.

Psychodelics to me was one of these categories where the answer isn't there yet

and has the most potential to be one of the most radically changing medical practices of the next decade.

So Natasha, this came up in Danny's five startup theses that will transform the 20-20s piece.

When you read this, were you surprised to see

...